HOME >> MEDICINE >> NEWS
Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., South San Francisco, Calif., which manufactures bevacizumab, provided bevacizumab for the trial under the Cooperative Research and Development Agreement (CRADA) with NCI for the clinical development of bevacizumab.

The Data Monitoring Committee overseeing the trial (known as E4599)* recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of improving overall survival. Researchers found that patients in the study who received bevacizumab in combination with standard chemotherapy (a treatment regimen of paclitaxel and carboplatin) had a median overall survival of 12.5 months compared to patients treated with the standard chemotherapy alone, who had a median survival of 10.2 months. This difference is statistically significant. Detailed results from this trial will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) to be held in Orlando, Fla., on May 13-17, 2005.

"The exciting results of this randomized study reveal, for the first time, an improvement in survival with the addition of a targeted agent to standard chemotherapy in this patient population," said Study Chair Alan B. Sandler, M.D., of the Vanderbilt University Medical Center in Nashville, Tenn.

"This study demonstrates that mechanistic-based interventions such as angiogenesis inhibitors are making important contribution
'"/>

Contact: NCI Press Officers
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
14-Mar-2005


Page: 1 2 3

Related medicine news :

1. Tuberculosis drug combined with virtual reality therapy is effective in treating fear of heights
2. Detrol LA combined with standard treatment for enlarged prostate is twice as effective
3. Nicotine more addictive when combined with other tobacco smoke chemicals, UCI study finds
4. Cognitive behavioral therapy combined with antidepressant effective in treating adolescent OCD
5. Heart disease kills more women annually than all cancers combined
6. Stents combined with clot-busting drugs effective in limiting impact of deadly form of stroke
7. Study shows people with Alzheimers can benefit from exercise combined with caregiver training
8. Wyeth chemists honored for Prevnar first combined pneumococcal vaccine for infants
9. Task force issues caution on combined hormone therapy
10. University of Pittsburgh research shows combined PET/CT finds cancerous lesions standard CT misses
11. Some patients are candidates for combined heart bypass, lung transplant surgeries

Post Your Comments:
(Date:4/27/2015)... PREVENT Life Safety, America’s premier provider of life ... addition of an account manager in Houston. In order ... customer base, Curtis Rice, an experienced sales professional, has ... Curtis has been added to the team to generate ... area and beyond. , Curtis brings with ...
(Date:4/27/2015)... 27, 2015 Health conscious businesses in ... first-of-its-kind bakery right on their doorstep, which will offer ... on restrictive and low-carbohydrate diets. This nut-based ... starch free, and will use only natural sweeteners like ... 2015, strives to provide specialty food that is currently ...
(Date:4/27/2015)... April 27, 2015 Jvion, the Atlanta-based ... Atlanta Pacesetter and recognized as one of the top ... award, which is presented by the Atlanta Business Chronicle, ... accelerate Atlanta’s status as an economic capital and employment ... success is spurred by the growing need to improve ...
(Date:4/26/2015)... York (PRWEB) April 26, 2015 ... 21, 2015 in the U.S. District Court, Northern ... lawsuits ( http://www.testosteronelawsuithub.com/ ) have been consolidated ... to court documents, matters addressed included the intention ... of claims involving their products on preemption grounds, ...
(Date:4/26/2015)... has released a new blog post explaining how to find ... to find low cost auto insurance is by comparing quotes. ... in a simple and convenient way. It is no longer ... prices. All the details are now freely available to anyone ... possible to compare online car insurance quotes on a single ...
Breaking Medicine News(10 mins):Health News:PREVENT Life Safety Services Welcomes Curtis Rice as a New Senior Account Manager in Houston, TX 2Health News:Nourish Bakery Serves Up Healthy Eating in Huntsville, Alabama 2Health News:Jvion Named to Top 40 Atlanta 2015 Pacesetters 2Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 2Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 3Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 4Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2
(Date:4/27/2015)... 27, 2015 TWi Pharmaceuticals, Inc. ("TWi") ... Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda ... Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to ... to TWi,s generic dexlansoprazole delayed release capsules for ... dosage strengths. An Abbreviated New Drug Application for TWi,s ...
(Date:4/25/2015)...  With the introduction of Elekta,s new Leksell Gamma ... now available for more patients with a wider variety ... radiosurgery system for the brain, integrates advanced motion management, ... of Gamma Knife radiosurgery. Elekta unveiled Leksell Gamma Knife ... in Barcelona . "This ...
(Date:4/24/2015)... , April 24, 2015  Perrigo Company plc ("Perrigo" ... rejection of the unsolicited offer from Mylan NV ("Mylan") ... outstanding shares of Perrigo for $60.00 per share in ... Perrigo share (the "Offer").  The Board ... share significantly undervalued the Company and its future growth ...
Breaking Medicine Technology:TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4
Cached News: